EVEREST MED (01952) received an additional 690,000 shares from the company's major shareholders.

Everest Med (01952) announced that the Board of Directors has been informed by non-executive director, Honorary Chairman of the Board, and major shareholder of the Company, Mr. Fu Wei, that on June 3, 2026, Cambridge Capital (as the major shareholder of the Company) purchased 690,000 shares of the Company's common stock in the market at a total cost of approximately HK$20 million, with an average price of approximately HK$28.93 per share. According to Mr. Fu Wei and Cambridge Capital, the purchase of shares through on-market acquisitions is based on their firm belief in the Company's future prospects and long-term development. Subject to compliance with applicable laws and regulations, Mr. Fu Wei and Cambridge Capital do not rule out the possibility of further increasing their holdings in the Company at an appropriate time.